You are here
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
The Australian Hospital Patient Costing Standards (AHPCS) provide direction for hospital patient costing through the development of standards for specific elements of the costing process and reporting requirements.
The AHPCS Version 4.0 was developed through extensive consultation with jurisdictions and stakeholders. The AHPCS Version 4.0 comprises:
This guide is intended to provide assistance when assigning care types, especially for those patients that may potentially have care that applies to more than one care type.